Halley Gilbert

CytomX Therapeutics, Inc. is committed to changing the treatment of cancer with our novel Probody® therapeutic platform. We have a broad pipeline comprised of five clinical-stage programs, with even more in development. Our commitment to transforming lives with safer, more effective therapies is driven by our curiosity and passion for innovation, and our belief that by acting with integrity in an honest, respectful, ethical manner, we have the power to change lives. Our workplace embodies collaboration, open communication, celebrating our successes and holding each other to the highest possible standards. CytomX embraces diversity and seeks to enhance and maintain our culture of equity and inclusion which encourages individuals to be themselves, feel involved, respected and connected. We at CytomX believe that we benefit from each other’s ideas and experiences. We accept our differences and learn from one another, improve together, and embrace change to achieve our corporate and individual objectives. This belief applies to how we work together at CytomX, how we work with others outside CytomX, how we represent CytomX in our communities, and how we endeavor to bring our scientific innovations to a diverse patient population. CytomX acknowledges the importance of diversity, equity and inclusion initiatives and that they require an evolving and ongoing commitment. CytomX is an equal opportunity employer and does not discriminate against any individual or potential candidate because of race, color, religion, sex, national origin, sexual preference or any other legally protected category. CytomX is located in South San Francisco, California, the birthplace of biotechnology. Learn more about us and how we are advancing science to treat cancer differently at www.cytomX.com.

Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease. Vaxcyte is re-engineering the way highly complex immunizations are made through modern synthetic techniques, including advanced chemistry and the XpressCFᵀᴹ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-31, a PCV with an expanded breadth of coverage of greater than 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease and VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.

Arcutis (Nasdaq: ARQT) was founded in 2016 to address significant unmet needs in medical dermatology. The company is an early commercial stage biopharmaceutical company focused on developing and commercializing best-in-class products. Our strategy is to exploit recent innovations in inflammation and immunology to bring the best molecules to bear against validated physiologic targets known to treat dermatological diseases and disorders. Our management team has extensive expertise in the development and commercialization of medical dermatology products, having held key leadership roles at a number of leading dermatology companies and, collectively, has successfully developed more than 50 FDA-approved products. We believe that by leveraging our team’s unique experience and demonstrated expertise to identify, develop and commercialize best-in-class molecules against validated targets, we will be able to develop differentiated products in less time, at lower cost, and at substantially lower risk than other approaches. Arcutis​ combination of vision, unmet medical need, experienced management and strategic approach has attracted support from leading investors in the life sciences sector.

CytomX Therapeutics, Inc. is committed to changing the treatment of cancer with our novel Probody® therapeutic platform. We have a broad pipeline comprised of five clinical-stage programs, with even more in development. Our commitment to transforming lives with safer, more effective therapies is driven by our curiosity and passion for innovation, and our belief that by acting with integrity in an honest, respectful, ethical manner, we have the power to change lives. Our workplace embodies collaboration, open communication, celebrating our successes and holding each other to the highest possible standards. CytomX embraces diversity and seeks to enhance and maintain our culture of equity and inclusion which encourages individuals to be themselves, feel involved, respected and connected. We at CytomX believe that we benefit from each other’s ideas and experiences. We accept our differences and learn from one another, improve together, and embrace change to achieve our corporate and individual objectives. This belief applies to how we work together at CytomX, how we work with others outside CytomX, how we represent CytomX in our communities, and how we endeavor to bring our scientific innovations to a diverse patient population. CytomX acknowledges the importance of diversity, equity and inclusion initiatives and that they require an evolving and ongoing commitment. CytomX is an equal opportunity employer and does not discriminate against any individual or potential candidate because of race, color, religion, sex, national origin, sexual preference or any other legally protected category. CytomX is located in South San Francisco, California, the birthplace of biotechnology. Learn more about us and how we are advancing science to treat cancer differently at www.cytomX.com.

Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease. Vaxcyte is re-engineering the way highly complex immunizations are made through modern synthetic techniques, including advanced chemistry and the XpressCFᵀᴹ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-31, a PCV with an expanded breadth of coverage of greater than 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease and VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.

Arcutis (Nasdaq: ARQT) was founded in 2016 to address significant unmet needs in medical dermatology. The company is an early commercial stage biopharmaceutical company focused on developing and commercializing best-in-class products. Our strategy is to exploit recent innovations in inflammation and immunology to bring the best molecules to bear against validated physiologic targets known to treat dermatological diseases and disorders. Our management team has extensive expertise in the development and commercialization of medical dermatology products, having held key leadership roles at a number of leading dermatology companies and, collectively, has successfully developed more than 50 FDA-approved products. We believe that by leveraging our team’s unique experience and demonstrated expertise to identify, develop and commercialize best-in-class molecules against validated targets, we will be able to develop differentiated products in less time, at lower cost, and at substantially lower risk than other approaches. Arcutis​ combination of vision, unmet medical need, experienced management and strategic approach has attracted support from leading investors in the life sciences sector.

Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates delivers the highest quality advice and novel solutions to legal challenges, enabling clients to achieve their business goals. We are known for the innovative and creative thinking we rely on to handle the most complex transactions, litigation/controversy issues, and regulatory matters, as well as the open, collaborative relationships we build with clients, including corporations; financial and governmental entities; small, entrepreneurial companies; and cultural, educational and charitable institutions. Our attorneys, who reflect a broad range of experiences and perspectives, collaborate seamlessly across our 21 offices in the world’s major financial centers.